|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SERPINB3 |
Gene summary for SERPINB3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SERPINB3 | Gene ID | 6317 |
| Gene name | serpin family B member 3 | |
| Gene Alias | HsT1196 | |
| Cytomap | 18q21.33 | |
| Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | P29508 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6317 | SERPINB3 | CA_HPV_1 | Human | Cervix | CC | 5.01e-20 | -6.87e-01 | 0.0264 |
| 6317 | SERPINB3 | CA_HPV_2 | Human | Cervix | CC | 3.51e-08 | -5.99e-01 | 0.0391 |
| 6317 | SERPINB3 | CA_HPV_3 | Human | Cervix | CC | 1.12e-05 | -4.43e-01 | 0.0414 |
| 6317 | SERPINB3 | HSIL_HPV_1 | Human | Cervix | HSIL_HPV | 1.32e-22 | -7.86e-01 | 0.0116 |
| 6317 | SERPINB3 | HSIL_HPV_2 | Human | Cervix | HSIL_HPV | 6.37e-19 | -7.36e-01 | 0.0208 |
| 6317 | SERPINB3 | N_HPV_1 | Human | Cervix | N_HPV | 9.55e-17 | -6.80e-01 | 0.0079 |
| 6317 | SERPINB3 | CCII_1 | Human | Cervix | CC | 2.45e-02 | -4.31e-01 | 0.3249 |
| 6317 | SERPINB3 | Tumor | Human | Cervix | CC | 4.18e-119 | 1.37e+00 | 0.1241 |
| 6317 | SERPINB3 | sample3 | Human | Cervix | CC | 9.29e-97 | 1.25e+00 | 0.1387 |
| 6317 | SERPINB3 | L1 | Human | Cervix | CC | 3.01e-44 | 1.13e+00 | 0.0802 |
| 6317 | SERPINB3 | T3 | Human | Cervix | CC | 3.09e-99 | 1.28e+00 | 0.1389 |
| 6317 | SERPINB3 | LZE5T | Human | Esophagus | ESCC | 1.48e-05 | 1.27e+00 | 0.0514 |
| 6317 | SERPINB3 | LZE8T | Human | Esophagus | ESCC | 4.02e-05 | 3.41e-01 | 0.067 |
| 6317 | SERPINB3 | LZE20T | Human | Esophagus | ESCC | 1.26e-02 | 2.03e-01 | 0.0662 |
| 6317 | SERPINB3 | P4T-E | Human | Esophagus | ESCC | 7.21e-12 | 8.10e-01 | 0.1323 |
| 6317 | SERPINB3 | P5T-E | Human | Esophagus | ESCC | 2.07e-74 | 2.37e+00 | 0.1327 |
| 6317 | SERPINB3 | P8T-E | Human | Esophagus | ESCC | 8.84e-05 | 6.21e-01 | 0.0889 |
| 6317 | SERPINB3 | P19T-E | Human | Esophagus | ESCC | 7.48e-03 | 9.14e-01 | 0.1662 |
| 6317 | SERPINB3 | P23T-E | Human | Esophagus | ESCC | 6.38e-25 | 2.44e+00 | 0.108 |
| 6317 | SERPINB3 | P26T-E | Human | Esophagus | ESCC | 9.53e-09 | 7.43e-01 | 0.1276 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003287314 | Cervix | HSIL_HPV | negative regulation of stress-activated MAPK cascade | 7/737 | 51/18723 | 3.65e-03 | 3.25e-02 | 7 |
| GO:007030314 | Cervix | HSIL_HPV | negative regulation of stress-activated protein kinase signaling cascade | 7/737 | 51/18723 | 3.65e-03 | 3.25e-02 | 7 |
| GO:005254824 | Cervix | N_HPV | regulation of endopeptidase activity | 36/534 | 432/18723 | 9.74e-09 | 1.72e-06 | 36 |
| GO:005254724 | Cervix | N_HPV | regulation of peptidase activity | 36/534 | 461/18723 | 5.15e-08 | 5.59e-06 | 36 |
| GO:001603225 | Cervix | N_HPV | viral process | 33/534 | 415/18723 | 1.23e-07 | 1.15e-05 | 33 |
| GO:004440324 | Cervix | N_HPV | biological process involved in symbiotic interaction | 26/534 | 290/18723 | 2.79e-07 | 2.12e-05 | 26 |
| GO:004586225 | Cervix | N_HPV | positive regulation of proteolysis | 29/534 | 372/18723 | 1.08e-06 | 5.80e-05 | 29 |
| GO:004586124 | Cervix | N_HPV | negative regulation of proteolysis | 27/534 | 351/18723 | 3.27e-06 | 1.36e-04 | 27 |
| GO:001095123 | Cervix | N_HPV | negative regulation of endopeptidase activity | 21/534 | 252/18723 | 1.21e-05 | 4.05e-04 | 21 |
| GO:001046623 | Cervix | N_HPV | negative regulation of peptidase activity | 21/534 | 262/18723 | 2.18e-05 | 6.16e-04 | 21 |
| GO:001905825 | Cervix | N_HPV | viral life cycle | 23/534 | 317/18723 | 4.35e-05 | 1.03e-03 | 23 |
| GO:005134624 | Cervix | N_HPV | negative regulation of hydrolase activity | 25/534 | 379/18723 | 9.66e-05 | 1.97e-03 | 25 |
| GO:004440925 | Cervix | N_HPV | entry into host | 14/534 | 151/18723 | 1.10e-04 | 2.18e-03 | 14 |
| GO:005212625 | Cervix | N_HPV | movement in host environment | 15/534 | 175/18723 | 1.53e-04 | 2.77e-03 | 15 |
| GO:001095223 | Cervix | N_HPV | positive regulation of peptidase activity | 16/534 | 197/18723 | 1.75e-04 | 3.00e-03 | 16 |
| GO:001095023 | Cervix | N_HPV | positive regulation of endopeptidase activity | 15/534 | 179/18723 | 1.96e-04 | 3.32e-03 | 15 |
| GO:005170125 | Cervix | N_HPV | biological process involved in interaction with host | 15/534 | 203/18723 | 7.48e-04 | 9.41e-03 | 15 |
| GO:004671825 | Cervix | N_HPV | viral entry into host cell | 12/534 | 144/18723 | 8.76e-04 | 1.07e-02 | 12 |
| GO:003287323 | Cervix | N_HPV | negative regulation of stress-activated MAPK cascade | 6/534 | 51/18723 | 3.17e-03 | 2.64e-02 | 6 |
| GO:007030323 | Cervix | N_HPV | negative regulation of stress-activated protein kinase signaling cascade | 6/534 | 51/18723 | 3.17e-03 | 2.64e-02 | 6 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa051465 | Cervix | CC | Amoebiasis | 29/1267 | 102/8465 | 3.31e-04 | 1.70e-03 | 1.01e-03 | 29 |
| hsa0514612 | Cervix | CC | Amoebiasis | 29/1267 | 102/8465 | 3.31e-04 | 1.70e-03 | 1.01e-03 | 29 |
| hsa051468 | Oral cavity | OSCC | Amoebiasis | 59/3704 | 102/8465 | 2.78e-03 | 7.17e-03 | 3.65e-03 | 59 |
| hsa0514615 | Oral cavity | OSCC | Amoebiasis | 59/3704 | 102/8465 | 2.78e-03 | 7.17e-03 | 3.65e-03 | 59 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SERPINB3 | SNV | Missense_Mutation | c.1099N>G | p.His367Asp | p.H367D | P29508 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-B6-A0I9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |
| SERPINB3 | SNV | Missense_Mutation | rs747263941 | c.1063N>A | p.Ser355Thr | p.S355T | P29508 | protein_coding | tolerated(0.59) | benign(0.001) | TCGA-B6-A0RV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| SERPINB3 | SNV | Missense_Mutation | rs143123968 | c.431G>A | p.Arg144Gln | p.R144Q | P29508 | protein_coding | tolerated(0.09) | benign(0.394) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD |
| SERPINB3 | SNV | Missense_Mutation | c.386N>G | p.Thr129Ser | p.T129S | P29508 | protein_coding | tolerated(0.05) | benign(0.035) | TCGA-E2-A158-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | arimidex | SD | |
| SERPINB3 | SNV | Missense_Mutation | novel | c.790N>A | p.Glu264Lys | p.E264K | P29508 | protein_coding | tolerated(0.06) | possibly_damaging(0.901) | TCGA-XX-A89A-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SERPINB3 | SNV | Missense_Mutation | novel | c.1144N>A | p.Leu382Ile | p.L382I | P29508 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| SERPINB3 | SNV | Missense_Mutation | novel | c.792N>C | p.Glu264Asp | p.E264D | P29508 | protein_coding | tolerated(0.12) | benign(0.044) | TCGA-FU-A40J-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | carboplatin | CR |
| SERPINB3 | SNV | Missense_Mutation | rs750555422 | c.912N>T | p.Met304Ile | p.M304I | P29508 | protein_coding | tolerated(0.11) | benign(0.08) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| SERPINB3 | SNV | Missense_Mutation | c.1149N>A | p.Phe383Leu | p.F383L | P29508 | protein_coding | deleterious(0) | possibly_damaging(0.896) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| SERPINB3 | SNV | Missense_Mutation | c.33N>A | p.Phe11Leu | p.F11L | P29508 | protein_coding | tolerated(0.09) | benign(0.136) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 6317 | SERPINB3 | KINASE, PROTEASE INHIBITOR, DRUGGABLE GENOME | GONADOTROPINS | 8070597 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |